Sequential gonadotrophin-releasing hormone agonist/low-dose oral contraceptive treatment for leiomyomata uteri.

Balasch J, Manau D, Mimó J, Durán M, Puerto B, Vanrell JA

Human reproduction (Oxford, England)1 Mar 1995Cited by 1 (Europe PMC)

PMID7782427DOI10.1093/oxfordjournals.humrep.a135983PepBankPUB-07782427

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

01HumanNon-randomized trialEfficacy outcome
In women with uterine leiomyomata, Decapeptyl significantly reduced mean uterine volume during treatment.
In plain wordsIn women with uterine fibroids, Decapeptyl reduced average uterine volume during treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseUterine volume during agonist treatment
Study
n = 6
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Six premenopausal women with leiomyomata uteri were treated with D-tryptophan-6-luteinizing hormone-releasing hormone (D-Trp-6-LHRH) depot (Decapeptyl 3.75) for 6 months and demonstrated a significant reduction in mean uterine volume.
1 context sentence(design, population, supporting numbers)
Summary · context
A low-dose oral contraceptive containing 30 micrograms of ethinyl oestradiol plus 150 micrograms of desogestrel was given during the ensuing 12 months.
Report a problemFND-0778242701

Studies that did not test the peptide alone1

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome
After Decapeptyl withdrawal and subsequent oral contraception, fibroids rapidly regrew and uterine volume reached or exceeded pretreatment values.
In plain wordsAfter Decapeptyl withdrawal and subsequent oral contraception, fibroids regrew and uterine volume reached or exceeded pretreatment values.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseFibroid regrowth after sequential treatment
Study
n = 6
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
When GnRHa therapy was discontinued, there was a rapid regrowth of the uterine fibroids and the uterine volume had reached, or even exceeded, pretreatment values by the eighth to 12th month of contraceptive therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
Six premenopausal women with leiomyomata uteri were treated with D-tryptophan-6-luteinizing hormone-releasing hormone (D-Trp-6-LHRH) depot (Decapeptyl 3.75) for 6 months and demonstrated a significant reduction in mean uterine volume.
Summary · context
A low-dose oral contraceptive containing 30 micrograms of ethinyl oestradiol plus 150 micrograms of desogestrel was given during the ensuing 12 months.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-0778242702

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.